Integra LifeSciences Holdings (IART) has wrapped up FY 2025 with Q4 revenue of US$434.9 million, while reporting a basic EPS loss of US$0.02 and net income loss of US$1.7 million, setting a cautious tone around profitability. The company has seen quarterly revenue move from US$442.6 million in Q4 2024 to US$434.9 million in Q4 2025, against a backdrop of trailing 12 month revenue of about US$1.6 billion and a basic EPS loss of US$6.74 over that same period. Margins are clearly under pressure and will likely be front and center for investors weighing the long term earnings story.

See our full analysis for Integra LifeSciences Holdings.

With the headline numbers on the table, the next step is to compare this earnings profile with the widely held bullish and bearish narratives around Integra LifeSciences and assess whether the latest margin picture supports or challenges those views.

Net loss of US$516 million over the year

• On a trailing 12 month basis, Integra reported net income loss of about US$516.5 million on US$1.6b of revenue, compared with quarterly net income loss of US$1.7 million on US$434.9 million in Q4 2025.
• Consensus narrative points to longer term margin improvement. However, this recent loss profile still lines up with concerns about high leverage and remediation costs:
  • Analysts expect profit margins to move from about a 30.9% loss today to a 4.9% margin in three years, but current trailing losses highlight how much needs to change for that to happen.
  • At the same time, net debt of US$1.59b at 4.5x EBITDA in the consensus narrative sits uncomfortably next to these losses and the comment that interest payments are not well covered by earnings.

2.7% revenue growth vs 10.4% market

• Revenue over the last 12 months is growing at 2.7% per year, which is slower than the cited 10.4% per year for the broader US market, while quarterly revenue has moved between US$382.7 million and US$434.9 million across FY 2025.
• Bulls argue that supply chain and compliance fixes can lift growth, and the current numbers partly frame that opportunity but also the challenge:
  • Bullish assumptions in the narrative use revenue growth of 4.9% per year for the next three years, a step up from the current 2.7% rate that would rely on product relaunches and new capacity such as the Braintree facility.
  • The recent history of shipholds, recalls, and remediation costs in the bullish story helps explain why trailing growth is modest and why any acceleration would first need those operational issues to be fully resolved.

Bulls see these earnings as the low point before supply chain fixes and higher growth show up in the numbers, while the current 2.7% revenue pace and large trailing loss keep the bar high for that turnaround. 🐂 Integra LifeSciences Holdings Bull Case

DCF fair value and low P/S vs risks

• With the share price at US$11.33, the stock is trading below a DCF fair value of about US$19.64 and on a P/S of 0.5x compared with peers at 4.6x and a US Medical Equipment industry average of 2.9x.
• Bears focus on whether the business can earn enough to justify even these low multiples, and the current results give them specific points to lean on:
  • Bears highlight that the company is unprofitable on a trailing 12 month basis and that losses have grown at about 68.5% per year over the past five years, which is a sharp contrast to valuation work that assumes a return to positive earnings.
  • They also point to interest payments not being well covered by earnings, which matters a lot when net income loss is around US$516.5 million and leverage is already flagged as high in the consensus narrative.

Skeptics see the wide gap between the current US$11.33 price and DCF fair value of US$19.64 as only meaningful if the company can move away from repeated losses and improve interest coverage. 🐻 Integra LifeSciences Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Integra LifeSciences Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this combination of cautious and optimistic signals has you undecided, do not wait for the next quarter to form an opinion. Instead, review the full balance of 3 key rewards and 1 important warning sign and decide where you stand.

Explore Alternatives

Integra LifeSciences is working through sizeable losses, pressured margins, high remediation costs, and net debt of about US$1.59b at 4.5x EBITDA.

If that mix of losses and leverage feels uncomfortable, it is a good time to check out solid balance sheet and fundamentals stocks screener (41 results) that prioritize stronger financial footing and more resilient balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.